Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 6/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.41 |
| ▸ | HRH2 | P25021 | 7/20 | 0.39 |
| ▸ | HRH1 | P35367 | 7/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 5/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | KDM5A | P29375 | 2/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30284659 | 0.99 | GNAI3 (0.40) | GNAI3GNAI1HRH2HRH1L3MBTL1 | |
| SCHEMBL30299418 | 0.99 | GNAI3 (0.40) | GNAI3GNAI1HRH2HRH1L3MBTL1 | |
| SCHEMBL20618496 | 0.99 | GNAI3 (0.40) | GNAI3GNAI1HRH2HRH1L3MBTL1 | |
| SCHEMBL19040726 | 0.99 | GNAI3 (0.40) | GNAI3GNAI1HRH2HRH1L3MBTL1 | |
| SCHEMBL20618494 | 0.99 | GNAI3 (0.40) | GNAI3GNAI1HRH2HRH1L3MBTL1 | |
| SCHEMBL29329334 | 0.99 | GNAI3 (0.40) | GNAI3GNAI1HRH2HRH1L3MBTL1 | |
| SCHEMBL21423426 | 0.99 | GNAI3 (0.40) | GNAI3GNAI1HRH2HRH1L3MBTL1 | |
| SCHEMBL22534819 | 0.99 | GNAI3 (0.40) | GNAI3GNAI1HRH2HRH1L3MBTL1 | |
| SCHEMBL19032602 | 0.99 | GNAI3 (0.40) | GNAI3GNAI1HRH2HRH1L3MBTL1 | |
| SCHEMBL19635522 | 0.93 | GNAI3 (0.38) | GNAI3GNAI1HRH2HRH1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210161829-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-06-03 | — | — | US | disclosed |
| US-20190002890-A1 | POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | ARES CAPITAL CORPORATION, AS AGENT | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002890-A1 | POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | GBA1, GAA, GLA | GNAI3 339/4885GNAI1 739/4885HRH2 4782/4885 |
| US-20210161829-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | LNPK, PLTP, PHOSPHO1 | GNAI3 1599/4885GNAI1 1739/4885HRH2 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.